Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin

Hirosuke Yamaji, Takashi Murakami, Kazuyoshi Hina, Shunichi Higashiya, Hiroshi Kawamura, Masaaki Murakami, Shigeshi Kamikawa, Satoshi Hirohata, Shozo Kusachi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Different target activated clotting times (ACTs) during atrial fibrillation (AF) ablation have been proposed. Moreover, relationships between initial bolus dose of heparin at the start of AF ablation in patients receiving edoxaban anticoagulation therapy and ACT are unclear. Methods: Patients who received anticoagulation with uninterrupted warfarin (control; n = 120) or interrupted edoxaban (n = 120) on the morning of day of ablation were studied. An initial dose of 100 U/kg heparin was administered as a reliable control for warfarin. Initial heparin doses of 120, 130, 140, or 150 U/kg were randomly administered to the edoxaban group. Results: Edoxaban group showed shorter baseline ACT before the procedure (130 ± 16 seconds) than the warfarin group (152 ± 26 seconds, P < 0.0001). In the warfarin group, 100 U/kg heparin showed 361 ± 48 seconds 15-minute ACT. In the edoxaban group, an increase in initial dose induced prolongation of 15-minute ACT (i.e., 15-minute ACTs of 293 ± 56, 306 ± 39, 311 ± 45, and 319 ± 45 seconds for 120, 130, 140, and 150 U/kg initial doses, respectively). The total heparin required during the procedure was higher in the edoxaban group than in the warfarin group (109 ± 37 vs. 77 ± 21 U/kg/h, P < 0.0001). The 120–150 U/kg dose of heparin in edoxaban group did not cause thromboembolic or major bleeding complications. Conclusion: Edoxaban interrupted on the day of ablation showed a shorter baseline ACT than uninterrupted warfarin. Edoxaban required a higher initial heparin dose to achieve a similar 15-minute ACT to warfarin. These results are useful for determining the initial heparin dose required to achieve variable target ACTs.

Original languageEnglish
Pages (from-to)835-843
Number of pages9
JournalJournal of Cardiovascular Electrophysiology
Volume29
Issue number6
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Warfarin
Atrial Fibrillation
Heparin
edoxaban
Hemorrhage

Keywords

  • anticoagulation
  • atrial fibrillation
  • catheter ablation
  • edoxaban
  • stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin. / Yamaji, Hirosuke; Murakami, Takashi; Hina, Kazuyoshi; Higashiya, Shunichi; Kawamura, Hiroshi; Murakami, Masaaki; Kamikawa, Shigeshi; Hirohata, Satoshi; Kusachi, Shozo.

In: Journal of Cardiovascular Electrophysiology, Vol. 29, No. 6, 01.06.2018, p. 835-843.

Research output: Contribution to journalArticle

Yamaji, Hirosuke ; Murakami, Takashi ; Hina, Kazuyoshi ; Higashiya, Shunichi ; Kawamura, Hiroshi ; Murakami, Masaaki ; Kamikawa, Shigeshi ; Hirohata, Satoshi ; Kusachi, Shozo. / Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin. In: Journal of Cardiovascular Electrophysiology. 2018 ; Vol. 29, No. 6. pp. 835-843.
@article{74ffc043c9a5441989d9835951412fed,
title = "Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin",
abstract = "Background: Different target activated clotting times (ACTs) during atrial fibrillation (AF) ablation have been proposed. Moreover, relationships between initial bolus dose of heparin at the start of AF ablation in patients receiving edoxaban anticoagulation therapy and ACT are unclear. Methods: Patients who received anticoagulation with uninterrupted warfarin (control; n = 120) or interrupted edoxaban (n = 120) on the morning of day of ablation were studied. An initial dose of 100 U/kg heparin was administered as a reliable control for warfarin. Initial heparin doses of 120, 130, 140, or 150 U/kg were randomly administered to the edoxaban group. Results: Edoxaban group showed shorter baseline ACT before the procedure (130 ± 16 seconds) than the warfarin group (152 ± 26 seconds, P < 0.0001). In the warfarin group, 100 U/kg heparin showed 361 ± 48 seconds 15-minute ACT. In the edoxaban group, an increase in initial dose induced prolongation of 15-minute ACT (i.e., 15-minute ACTs of 293 ± 56, 306 ± 39, 311 ± 45, and 319 ± 45 seconds for 120, 130, 140, and 150 U/kg initial doses, respectively). The total heparin required during the procedure was higher in the edoxaban group than in the warfarin group (109 ± 37 vs. 77 ± 21 U/kg/h, P < 0.0001). The 120–150 U/kg dose of heparin in edoxaban group did not cause thromboembolic or major bleeding complications. Conclusion: Edoxaban interrupted on the day of ablation showed a shorter baseline ACT than uninterrupted warfarin. Edoxaban required a higher initial heparin dose to achieve a similar 15-minute ACT to warfarin. These results are useful for determining the initial heparin dose required to achieve variable target ACTs.",
keywords = "anticoagulation, atrial fibrillation, catheter ablation, edoxaban, stroke",
author = "Hirosuke Yamaji and Takashi Murakami and Kazuyoshi Hina and Shunichi Higashiya and Hiroshi Kawamura and Masaaki Murakami and Shigeshi Kamikawa and Satoshi Hirohata and Shozo Kusachi",
year = "2018",
month = "6",
day = "1",
doi = "10.1111/jce.13483",
language = "English",
volume = "29",
pages = "835--843",
journal = "Journal of Cardiovascular Electrophysiology",
issn = "1045-3873",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin

AU - Yamaji, Hirosuke

AU - Murakami, Takashi

AU - Hina, Kazuyoshi

AU - Higashiya, Shunichi

AU - Kawamura, Hiroshi

AU - Murakami, Masaaki

AU - Kamikawa, Shigeshi

AU - Hirohata, Satoshi

AU - Kusachi, Shozo

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: Different target activated clotting times (ACTs) during atrial fibrillation (AF) ablation have been proposed. Moreover, relationships between initial bolus dose of heparin at the start of AF ablation in patients receiving edoxaban anticoagulation therapy and ACT are unclear. Methods: Patients who received anticoagulation with uninterrupted warfarin (control; n = 120) or interrupted edoxaban (n = 120) on the morning of day of ablation were studied. An initial dose of 100 U/kg heparin was administered as a reliable control for warfarin. Initial heparin doses of 120, 130, 140, or 150 U/kg were randomly administered to the edoxaban group. Results: Edoxaban group showed shorter baseline ACT before the procedure (130 ± 16 seconds) than the warfarin group (152 ± 26 seconds, P < 0.0001). In the warfarin group, 100 U/kg heparin showed 361 ± 48 seconds 15-minute ACT. In the edoxaban group, an increase in initial dose induced prolongation of 15-minute ACT (i.e., 15-minute ACTs of 293 ± 56, 306 ± 39, 311 ± 45, and 319 ± 45 seconds for 120, 130, 140, and 150 U/kg initial doses, respectively). The total heparin required during the procedure was higher in the edoxaban group than in the warfarin group (109 ± 37 vs. 77 ± 21 U/kg/h, P < 0.0001). The 120–150 U/kg dose of heparin in edoxaban group did not cause thromboembolic or major bleeding complications. Conclusion: Edoxaban interrupted on the day of ablation showed a shorter baseline ACT than uninterrupted warfarin. Edoxaban required a higher initial heparin dose to achieve a similar 15-minute ACT to warfarin. These results are useful for determining the initial heparin dose required to achieve variable target ACTs.

AB - Background: Different target activated clotting times (ACTs) during atrial fibrillation (AF) ablation have been proposed. Moreover, relationships between initial bolus dose of heparin at the start of AF ablation in patients receiving edoxaban anticoagulation therapy and ACT are unclear. Methods: Patients who received anticoagulation with uninterrupted warfarin (control; n = 120) or interrupted edoxaban (n = 120) on the morning of day of ablation were studied. An initial dose of 100 U/kg heparin was administered as a reliable control for warfarin. Initial heparin doses of 120, 130, 140, or 150 U/kg were randomly administered to the edoxaban group. Results: Edoxaban group showed shorter baseline ACT before the procedure (130 ± 16 seconds) than the warfarin group (152 ± 26 seconds, P < 0.0001). In the warfarin group, 100 U/kg heparin showed 361 ± 48 seconds 15-minute ACT. In the edoxaban group, an increase in initial dose induced prolongation of 15-minute ACT (i.e., 15-minute ACTs of 293 ± 56, 306 ± 39, 311 ± 45, and 319 ± 45 seconds for 120, 130, 140, and 150 U/kg initial doses, respectively). The total heparin required during the procedure was higher in the edoxaban group than in the warfarin group (109 ± 37 vs. 77 ± 21 U/kg/h, P < 0.0001). The 120–150 U/kg dose of heparin in edoxaban group did not cause thromboembolic or major bleeding complications. Conclusion: Edoxaban interrupted on the day of ablation showed a shorter baseline ACT than uninterrupted warfarin. Edoxaban required a higher initial heparin dose to achieve a similar 15-minute ACT to warfarin. These results are useful for determining the initial heparin dose required to achieve variable target ACTs.

KW - anticoagulation

KW - atrial fibrillation

KW - catheter ablation

KW - edoxaban

KW - stroke

UR - http://www.scopus.com/inward/record.url?scp=85044513728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044513728&partnerID=8YFLogxK

U2 - 10.1111/jce.13483

DO - 10.1111/jce.13483

M3 - Article

VL - 29

SP - 835

EP - 843

JO - Journal of Cardiovascular Electrophysiology

JF - Journal of Cardiovascular Electrophysiology

SN - 1045-3873

IS - 6

ER -